Drug intelligence / Profile preview

risperidone + olanzapine + quetiapine + ziprasidone + aripiprazole

Development stage: Preclinical
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral, Intramuscular

Overview

This is a combination of five atypical antipsychotic medications. Each component has different receptor binding profiles and mechanisms of action, which may produce synergistic effects when used in combination. These medications are primarily used to treat schizophrenia, schizoaffective disorder, and bipolar disorder. While individual components have established efficacy, the use of all five medications simultaneously is not a standard clinical practice and would be considered polypharmacy.

Targets

ADRA1A (α1A)ADRA2A (α2A)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on risperidone + olanzapine + quetiapine + ziprasidone + aripiprazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on risperidone + olanzapine + quetiapine + ziprasidone + aripiprazole.